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ABSTRACT
Seventy patients of schizophrenia were divided into two groups based on the presence or absence of substance abusing history in
them. Two groups were compared on various socio-demographic and clinical variables. Thirty-eight (54.3%) patients could be diagnosed
as having comorbid alcohol/substance abuse/dependence. Seventeen (24.3%) of them were poly-substance abusers. Comorbid
substance abusers were predominantly represented by positive syndrome while non-abusers by negative syndrome. In contrast to the
report by the most western researchers, most patients in the present study with a diagnosis of substance abusing schizophrenia were
married. Similar study from a developing country is rare in the existing literature.
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Recent years have attracted considerable interest in the
dual problem of schizophrenia and substance abuse (Selzer
et al., 1993; Smith et al., 1994; Turner et al., 1997; Buckley,
1998). High rates of substance abuse comorbidity in
schizophrenia have consistently been found in clinical
samples (Drake et al., 1989; Dixon et al., 1991) as well as
in epidemiologic surveys (Regier et al., 1990; Fowler et al.,
1998). Older studies (Mueser et al., 1990) reported that
substance abusing schizophrenia patients tend to be young
males of low socio-economic status with history of fewer
previous hospitalisations. These patients also have greater
likelihood of family history of drug abuse (Tsuang et al.,
1982). Some studies found an association between substance
abuse and positive psychotic symptoms (Pulver et al., 1989),
whereas others reported no such association (Dixon et al.,
1990; Drake et al., 1989).
In the field of comorbidity research in relation to
schizophrenia population, only few studies have been
reported from India till date. Dube and Handa (1971)
conducted a general population study in which 13.69% of
schizophrenia patients were found to be using drugs. Trivedi
and Sethi (1978) reported 16.5% schizophrenia patients
were abusing drugs, mainly alcohol and cannabis. Goswami
(1996) reported substance-abusing group had significantly
less symptoms than non-substance abusing schizophrenics
on global psychopathology and positive symptoms following
a cross-sectional comparative study between 22 substance
abusing and 22 non-abusing schizophrenia patients. His
sample constituted of both in- and out-patient schizophrenia
populations. Aim of the present study was to find out the
prevalence of substance abuse comorbidity in hospitalised
schizophrenia population, and to compare patients of
schizophrenia with and without substance abuse history on
various demographic and clinical variables.
Material and Method
The study was conducted at the Central Institute of
Psychiatry, Kanke, Ranchi, India. We interviewed all the
consecutive male patients, admitted between 1st march 1998
and 30th September 1998, who had a diagnosis of
schizophrenia. During the study period a total number of
88 patients were screened, of which 70 patients who fulfilled
the DSM-IIIR criteria for schizophrenia, and who gave the
consent to participate, were taken up for the study. Total
sample was divided into 2 groups based on the presence or
absence of alcohol or drug abuse/dependence as defined
by DSM-IIIR criteria. Thus the study population
comprised of patients with a diagnosis of schizophrenia and
comorbid drug or alcohol abuse/dependence (SAS group)
and the control population comprised of schizophrenia
patients with no drug or alcohol abuse history (NSAS group).
In the present study, substance/alcohol abusers/dependents
were considered as a single group. This simplification is
useful for the purpose of analysis and is based on the
international trend in the comorbidity research. Inclusion
Criteria being male patients with a DSM-IIIR diagnosis136
of schizophrenia in the age range of 18-45 years. Exclusion
Criteria were the evidence of organicity either from history,
clinical examination or laboratory examination, patients who
did not give consent to participate in the study, and any
comorbid major psychiatric disorder or mental retardation.
Assessment tools used were ‘Structured Clinical
Interview Schedule for DSM-IIIR’ (SCID-P. Spitzer et al.,
1987) and ‘Positive and Negative Syndrome Scale’
(PANSS, Kay et al., 1987).
The Structured Clinical Interview Schedule for DSM-IIIR
(SCID) is a semi-structured interview schedule for making
the major axis-I and axis-II diagnoses. The PANSS was
developed, as a more rigorously operationalised method for
evaluating positive, negative and other symptom dimensions
in schizophrenia. A series of studies provided enough
evidence of suitable psychometric properties of the PANSS
for typological and dimensional assessment of distinct
syndromes in schizophrenia (Kay et al., 1988). Good to
excellent reliabilities were found on all scale scores and
most items of the PANSS (Bell et al., 1992).
Assessment Technique
At the time of the admission, we interviewed patient’s
relatives to gather information about the index episode, as
well as about the previous episodes of psychiatric illnesses,
if any. Information regarding the history of substance abuse
or dependence was also gathered from relatives and close
friends. Necessary socio-demographic, illness and treatment
variables were recorded in a specially designed clinical
datasheet.
Each of the patients who satisfied the inclusion criteria was
interviewed within 48 hours of the admission to the hospital.
Interview was conducted using SCID-P, for confirming the
diagnosis of schizophrenia and drug or alcohol abuse/
dependence, if any. Severity of psychopathology was
assessed by using PANSS. Patients were classified as
“positive subtype” if they scored three or more moderate
ratings on the positive scale but fewer than three moderate
ratings on the negative scale. Patients were classified as
“negative subtype” if they exhibit the opposite pattern; i.e.,
at least three moderate ratings on the negative scale but
fewer than three moderate ratings on the positive scale.
Patients who score at least three moderate ratings on both
the scales were regarded as “mixed type”. Routine blood
and biochemical investigations and special investigations,
as and when needed, were done to rule out the possibility
of organic schizophrenia like disorders.
Statistical Analysis
Besides descriptive statistics, ‘t’ test was applied for the
continuous data and ‘Chi-square’ test was performed to
the categorical data.
Results
Thirty-eight (54.3%) patients had a history of substance
abuse/dependence, whereas rest 32 (45.7%) were not
abusing any drugs prior to the onset or during the period of
illness. Nine (12.8%) patients were abusing or dependent
on cannabis, 3 (4.3%) on alcohol, 9 (12.8%) on nicotine
and 17 (24.3%) patients were polysubstance abusers/
dependents.
When we tried to see the types of substances abused by
the ‘schizophrenia patients with polysubstance abuser’
group we found that six patients were 2 drugs abusers;
rest 11 patients were abusing 3 or more drugs/alcohol
simultaneously. Thus, we got a revised picture of individual
drug/alcohol abuse by the substance abusing schizophrenia
population (Table 1)
Table: 1. Overall percentage of individual drugs being abused by
Substance Abusing Schizophrenics (N= 38):
Psychoactive SAS Total
Substances N=38 % Sample %
N=70
Cannabis 23 60.5 233 2.8
Alcohol 16 42.1 16 22.8
Nicotine 2360.5 233 2.8
Opioid 2 5.32 2.8
SAS : Substance Abusing Schizophrenics
Nicotine abusers include all forms of nicotine abusers, esp.
bidi, cigarette and khaini preparations.
When the entire sample population was divided according
to standard schizophrenia subtypes we got 29 paranoid, 8
catatonic, 5 disorganized, 13 undifferentiated and 4 cases
of residual schizophrenia. Further dividing them into
substance abusing and non-abusing groups did not reveal
any significant differences. However, when they were
divided according to clinical subtypes we got some
interesting findings (Table 3).
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Discussion
The sample of 70 schizophrenia patients compares
favourably with other similar studies done in this field
(Peralta et al., 1990; Dixon et al., 1991; Rosenthal et al.,
1994; Kovasznay et al., 1997). Amongst 70 schizophrenia
patients, 38 (54.3%) patients had a history of substance
abuse/dependence, whereas rest 32 (45.7%) were not
Table: 2
Comparison between Substance Abusing Schizophrenics (SAS) and Non-Substance
Abusing Schizophrenics (NSAS) across various Socio-Demographic and clinical variables:
Variable SAS NSAS Total (%) t/χ 2 value p
N=38 N=32
1. Age (in yr.): 31.5 (5.9) 30.5 (7.7) t=0.64 0.5
mean (SD)
2. Education (in yr.): 8.8 (4.1) 9.6 (4.6) t=0.78 0.4
mean (SD)
3. SES:
Lower 11 6 17 (24.2%) χ 2=0.98 0.3
Middle & above 27 26 53 (75.8)
4. Habitat
Rural 26 14 40 (57.1%) χ 2=4.3 0.04
Urban 12 18 30 (42.9%)
5. Marital Status:
Married 29 14 43 (61.4%) χ 2=7.78 <0.01*
Single 9 18 27 (38.6%)
6. Occupation
Unemployed 1317 3 0  (42.9%) χ 2=2.530.1
Employed 25 15 40 (57.1%)
7. Religion
Hindu 33 23 56 (80%) χ 2=2.430.1
Others 5 9 14 (20%)
8. Age of onset (in yr.)
Mean (SD) 25.5 (5.6) 24.3 (7.3) t=0.7 0.4
9. Present episode
(in yr.) Mean (SD) 3.6 (4.2) 4.8 (4.7) t=1.1 0.3
10. Stay in hospital
(in days)Mean (SD) 41.7 (17.4) 47.5 (19.2) t=1.30.2
11. Past history:
Absent 27 22 49 (70%) χ 2=0.04 0.8
Present 11 10 21 (30%)
12. F.H. of Schizophrenia
Absent 33 31 64 (91.4%) Fisher’s 0.1
Present 5 1 6 (8.6%) one tail test
13. F.H. of subs.  abuse
Absent 32 32 64 (91.4%) Fisher’s 0.2
Present 6 0 6 (8.6%) one tail test
* Significant at 0.01 level
SAS : Substance Abusing Schizophrenics
NSAS : Non-Substance Abusing Schizophrenics
F.H. : Family History
Table: 3. Schizophrenia syndromes and substance abuse:
Syndrome type SAS NSAS Total %
Positive 24 8 32 45.7
Negative 7 13 20 28.6
Mixed 7 11 18 25.7
Total 38 32 70 100
x2 = 10.25 DF= 2 p<0.01*
SAS : Substance Abusing Schizophrenics
NSAS: Non-Substance Abusing Schizophrenics
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abusing any drugs prior to the onset or during the period of
illness. This is comparable to the data available from
different epidemiological as well as clinical studies. ECA
study (Regier et al., 1990) reported a lifetime prevalence
of substance abuse in 47% of the schizophrenia population.
Dixon et al. (1991) reported 48%; Lehman et al. (1994)
reported 54%, Kovasznay et al. (1997) reported 43.8%,
Fowler et al. (1998) reported 59.8% and Canton-Graae et
al. (2001) reported 48.3% comorbid substance abuse in
their respective schizophrenia population.
When we separated the patients of schizophrenia into
traditional paranoid, catatonic, disorganized and
undifferentiated subtypes, two groups did not differ. But,
when we compared them in the light of clinical
‘schizophrenic syndrome’ subtypes we got a significant
(p<0.01) finding. It was seen that substance abusing
schizophrenics were clustered in the positive syndrome
group and that non-substance abuse schizophrenics
clustered in the negative and mixed syndrome group (Table
3). Amongst 38 substance abusing schizophrenics (SAS)
in the present study 24 (63.2%) met the criteria for positive
syndrome, 7 (18.4%) for negative syndrome and another 7
(18.4%) for mixed syndrome. Available literature on this
aspect of substance abusing schizophrenics is few till date.
Rosenthal et al. (1994) reported 7 (24.1%) amongst his 29
substance abusing schizophrenics met the criteria for
negative syndrome, five (16.7%) positive syndrome and 17
(58.6%) patients showed mixed syndrome. But they did
not have any substance non-abusers for comparative study.
Negreete et al. (1986) while studying a group of cannabis
abusing schizophrenia patients reported a global increase
in positive symptom score. But, Sevy et al. (1990) found no
relationship between history of cocaine abuse (including
mixed substance abuse) and global measures of positive,
negative and general symptoms using PANSS.
Older studies reported certain socio-demographic predictors
being differentially correlated with substance abuse in
schizophrenia population. These are male sex, younger age,
good premorbid adjustment, early age of first hospitalization,
poor treatment compliance, high relapse rate, etc. On the
contrary, recent studies with more rigorous inclusion and
exclusion criteria did not reveal any significant difference
between the two groups on most socio-demographic
variables. Our findings also confirm to this notion. As
revealed in Table 2, two groups did not differ on most
demographic and clinical variables. Nevertheless, one
significant finding (Table: 2) was that 76% of our SAS
populations were married, whereas only 44% of NSAS
patients were married. The difference was statistically
significant (p<0.01). Western literature mostly report an
opposite finding that majority of substance-abusing
population were unmarried or separated/ divorced (Drake
et al., 1989). The finding was even more interesting and
difficult to explain, as there was no significant difference
between the two groups in the mean age of onset of
schizophrenia (25.5 years for the SAS and 24.3 years for
the NSAS group).
In the present study, the prevalence of cannabis abuse/
dependence was 32.8%; alcohol 22.8%, nicotine 32.8%,
and opioid 2.8% of the total sample population. Available
literature reveals no consistent pattern of drug/alcohol abuse
amongst patients of schizophrenia. Fowler et al. (1998) in
his sample of schizophrenia patients found 48.4% abusing/
dependent on alcohol and 36.0% patients were abusing
cannabis. Cuffel et al. (1993) reported that in a sample of
231 schizophrenia patients with substance abuse, 37% were
abusing alcohol, 23% cannabis, 8% sedatives, 10% narcotics
and 13% were abusing stimulant drugs. Goswami (1996)
reported a high prevalence of opioid abusers (50%) in his
sample population. Such variability probably indicates that
availability, rather than the specific CNS effects of the drug,
determine the choice of drugs in schizophrenia patients
(‘environmental determinants’ of substance abuse, Dixon
et al., 1990).
Conclusion
Substance abuse comorbidity in schizophrenia was observed
to be a common phenomenon as 54.3% schizophrenia
patients could be marked as having additional diagnosis of
alcohol or other substance abuse/dependence. The two
groups did not differ significantly when they were separated
into traditional diagnostic sub-types of paranoid, catatonic,
disorganized and undifferentiated schizophrenia. SAS group
showed significantly high clustering of positive syndrome
and NSAS group aggregated more towards negative
syndrome domain. Contrary to the popular western notion,
there was higher prevalence of married subjects in the SAS
group. Finally, availability, rather than specific CNS effects,
probably determines the choice of drug/drugs in patients of
schizophrenia.
We envisage the following points as the limitations of the
present study:
Assessment of substance abuse comorbidity was based on
structured clinical interview (SCID) supplemented by the
information obtained from relatives or close friends.
Concurrent laboratory screening of blood and urine for drugs
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would have helped in confirmation of the diagnosis of
substance abuse disorder. This would perhaps increase the
prevalence of substance abuse disorder by eliminating under-
reporting.
For the purpose of the present study, two or more substance
abusers were grouped into the polysubstance abuser group;
though according to DSM-IV three or more substance
abusers should qualify as the polysubstance abusers.
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